Prognostic value of <sup>18</sup>F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with cutaneous angiosarcoma: A retrospective study of 18 cases

Umemura, Hiroshi; Kaji, Tatsuru; Hamada, Takeshi; Otsuka, Masaki; Asagoe, Kenji; Iwatsuki, Keiji

doi:10.1111/1346-8138.13839

Cited by 13 publications

(11 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positron emission tomography/CT is a combined imaging modality and has the advantage of generating quantitative information compared with CT. 20 The most commonly used radiotracer, FDG, is an analog of glucose, the uptake of which is proportional to cellular metabolic activity, and it is widely used in cancer imaging due to its sensitivity in detecting most malignant cells. 20,21 In the present study, internal malignancy (oropharyngeal cancer) was detected in one DM patient (case 11) by FDG-PET/CT. Furthermore, the FDG uptake is also observed in inflammatory cells.…”

Section: Discussionsupporting

confidence: 47%

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

Motegi

Fujiwara

Sekiguchi

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

18F‐Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is usually used to screen malignancy in patients with dermatomyositis (DM). Additionally, it is well known that FDG‐PET/CT provides valuable information for evaluating the activity of several inflammatory diseases, such as sarcoidosis, atherosclerosis, inflammatory bowel disease and rheumatoid arthritis. Therefore, the objective of this study was to evaluate the clinical usefulness of FDG‐PET/CT for the detection of inflammatory lesions and disease activity of both myopathy and interstitial lung disease (ILD) in DM patients. We measured the maximum standardized uptake value (SUVmax) in the muscles and lungs in 22 DM patients, and compared with magnetic resonance imaging (MRI) and high‐resolution computed tomography (HRCT) findings in the same muscle and lung regions as well as with clinical findings. We found that the location of increased FDG uptake was nearly consistent with the region of ILD and myositis detected by HRCT or MRI, respectively. There was a significant positive correlation between lung HRCT score and SUVmax in each lung. Serum Krebs von den Lungen‐6 levels also revealed significant positive correlation with total SUVmax of right and left lungs. Regarding FDG‐PET/CT and myopathy, total SUVmax in the muscles was significantly correlated with serum cytokeratin levels. Our results suggest that FDG uptake (SUVmax) might be useful for not only the detection of malignant tumors, but also the evaluation of the location and activity of ILD and myositis in DM patients.

show abstract

Section: Discussionsupporting

confidence: 47%

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

Motegi

Fujiwara

Sekiguchi

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…However, biopsy would likely be required to differentiate between the two entities. Although no systemic studies have been performed to evaluate the role of FDG PET-CT in angiosarcomas and related tumors, there are multiple reports of prominent metabolic activity being associated with angiosarcomas that have contributed to the management of patients in specific case reports and small series [ 76 , 77 ].…”

Section: Sarcomasmentioning

confidence: 99%

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Fine

Covington

Koppula

et al. 2022

Cancers

View full text Add to dashboard Cite

PET-CT is an advanced imaging modality with many oncologic applications, including staging, therapeutic assessment, restaging and surveillance for recurrence. The goal of this series of six review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for specific oncologic indications, the potential pitfalls and nuances that characterize these applications, and guidelines for image interpretation. Tumor-specific clinical information and representative PET-CT images are provided. The current, sixth article in this series addresses PET-CT in an evaluation of aggressive cutaneous malignancies, sarcomas and neuroendocrine tumors. A discussion of the role of FDG PET for all types of tumors in these categories is beyond the scope of this review. Rather, this article focuses on the most common malignancies in adult patients encountered in clinical practice. It also focuses on Food and Drug Agency (FDA)-approved and clinically available radiopharmaceuticals rather than research tracers or those requiring a local cyclotron. This information will serve as a guide to primary providers for the appropriate role of PET-CT in managing patients with cutaneous malignancies, sarcomas and neuroendocrine tumors. The nuances of PET-CT interpretation as a practical guide for imaging providers, including radiologists, nuclear medicine physicians and their trainees, are also addressed.

show abstract

“…However, because radiologists encounter cASs during the radiological interpretation for brain MR images in daily medical practice, 15 knowledge of unenhanced MR imaging findings is essential for the diagnosis of cAS of the scalp. On the other hand, some previous studies have evaluated MR imaging findings in cSCC of the head and neck 16 and 18 F-fluorodeoxyglucose ( 18 F-FDG)–positron emission tomography (PET)/computed tomography (CT) imaging findings in cAS 17 and cSCC. 18 To the best of our knowledge, there has been no study of comparative research with emphasis on unenhanced MR imaging findings and 18 F-FDG-PET/CT imaging findings in cAS and cSCC of the scalp.…”

Section: Introductionmentioning

confidence: 99%

Imaging findings of cutaneous angiosarcoma of the scalp: Comparison with cutaneous squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Purpose This study aimed to evaluate imaging findings of cutaneous angiosarcoma (cAS) of the scalp compared with those of cutaneous squamous cell carcinoma (cSCC). Methods This study included 15 patients with primary cAS and 10 with primary cSCC of the scalp. Seven patients with cAS and eight with cSCC underwent magnetic resonance imaging, and 11 patients with cAS and eight with cSCC underwent 18F-fluorodeoxyglucose–positron emission tomography/computed tomography imaging. Imaging findings for both pathologies were retrospectively reviewed and compared. Results All 15 cAS cases were elevated lesions with an obtuse angle, invading the subcutaneous fat tissue. Multiple lesions were observed in only five cAS cases (33%) and no cSCC cases. Maximum diameter-to-height ratio was significantly higher in cAS than in cSCC (3.3 ± 1.0 versus 2.3 ± 0.6; p < 0.01). On T2-weighted images, intratumoral hypointensity (86% versus 13%; p < 0.01) and mixed hyper- and hypointensity (71% versus 0%; p < 0.01) were observed more frequently in cAS than in cSCC. No significant differences were observed between cAS and cSCC regarding flow void (29% versus 25%; p = 0.656). Maximum standardized uptake values were marginally significantly lower in cAS than in cSCC (5.6 ± 3.1 versus 10.5 ± 6.6; p = 0.078). Conclusions Cases of cAS of the scalp always exhibited flat elevated lesions with invasion of the subcutaneous fat tissue. Compared with cSCC, intratumoral hypointensity and mixed hyper- and hypointensity on T2-weighted images were more frequent in cAS. These findings will help with the differential diagnosis of cAS.

show abstract

Prognostic value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with cutaneous angiosarcoma: A retrospective study of 18 cases

Cited by 13 publications

References 15 publications

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Imaging findings of cutaneous angiosarcoma of the scalp: Comparison with cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About

Prognostic value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with cutaneous angiosarcoma: A retrospective study of 18 cases

Cited by 13 publications

References 15 publications

Clinical value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

Clinical value of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

PET-CT in Clinical Adult Oncology—VI. Primary Cutaneous Cancer, Sarcomas and Neuroendocrine Tumors

Imaging findings of cutaneous angiosarcoma of the scalp: Comparison with cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About

Prognostic value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography in patients with cutaneous angiosarcoma: A retrospective study of 18 cases

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis

Clinical value of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis